Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Vermillion Taps McLain for CEO

Premium

Vermillion has appointed Thomas McLain as president and CEO. He replaces Bruce Huebner, who has served as interim CEO since last November when he took over for Gail Page.

Huebner will remain a director of the company.

Prior to joining Vermillion, McLain served as CEO and CFO of Claro Scientific. Before that, he held senior management positions at Nabi Biopharmaceuticals (now Biota Pharmaceuticals) and Bausch & Lomb. He has also served on the boards of Eastman Chemical, and the Biotechnology Industry Organization.

He holds an MBA in accounting and information systems from the University of Rochester, Simon Graduate School of Business, and a BA in economics from the College of the Holy Cross.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.